Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
SEQUOIA Trial Meets Primary PFS End Point Improvement With Frontline Zanubrutinib for CLL
August 2nd 2021The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.
Sintilimab Plus Bevacizumab Biosimilar IBI305 Demonstrates OS and PFS Benefit Over Sorafenib in HCC
July 23rd 2021Patients with unresectable hepatitis B virus–positive hepatocellular carcinoma have achieved significantly better overall survival and progression-free survival following treatment with sintilimab plus IBI305 vs sorafenib.
HuCART19 Achieved Durable, Robust Responses in Adult and Pediatric R/R B-ALL
July 14th 2021A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
As Cancer Screenings Increase in Late 2020, Racial and Economic Disparities Persist for Some Tests
July 8th 2021At the end of 2020, investigators saw more patients being screened for cancer compared with the beginning of the year, although racial and economic disparities still exist for certain tests.